Skip to main content
Figure 4 | Cancer Cell International

Figure 4

From: Targeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoter

Figure 4

In vitro gene expression and cell killing: (A - D) Meninglioma cells (M66) treated with Ad/CMV-GFP (A, C) or Ad/gTRAIL (B, D). Benign meningioma cells were treated with Ad/CMV-GFP or Ad/gTRAIL at 1000 MOI Expression of GFP or its fusion protein was revealed under a fluorescent microscope at 5 days after the treatment. (E-H) Glioma cells (U87) treated with Ad/CMV-GFP (E, G) or Ad/gTRAIL (F, H). Malignant Glioma cells treated with Ad/CMV-GFP or Ad/gTRAIL as described for meninglioma cells. Expressions of GFP or its fusion protein (A, B, E, F) were revealed under a fluorescent microscope. The cells morphologies (C, D, G, H) were revealed under regular microscope. Note, glioma cells treated with Ad/gTRAIL showed apoptosis morphology with the membrane blebbing and cell shrinkage and apoptosis.

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us